InvestSMART

Mesoblast Limited (ASX:MSB)

ALERT: Price-sensitive ASX Announcement for MSB
Current share price for MSB : $2.770 0.35 (14.46%)+
Announcement
Release
27 Feb 2026 8:49AM
Price at Release
$2.420
Full Release
download
Summary
Mesoblast Limited reported a successful commercial launch of RYONCIL, the first FDA-approved allogeneic mesenchymal stromal cell product, with significant revenue and gross margins. The company continues to invest in R&D and clinical trials, including Phase 3 trials for rexlemestrocel-L and REVASCOR® for chronic heart failure. Mesoblast anticipates strong financial performance in fiscal 2026 and maintains a robust cash position to support future growth and product development.
Key Points
  • Mesoblast received U.S. FDA approval for RYONCIL in December 2024.
  • RYONCIL is the first FDA-approved allogeneic mesenchymal stromal cell product.
  • RYONCIL launched in April 2025, with a net revenue of US$49 million in H1 FY26.
  • Strong gross margin of 93% for RYONCIL with significant R&D investment.
  • Successful U.S. commercial launch of RYONCIL boosting profitability.
  • Mesoblast anticipates full-year fiscal 2026 Ryoncil® net revenue between US$110 million and US$120 million.
  • Phase 3 trials ongoing for rexlemestrocel-L for chronic low back pain.
  • REVASCOR® is being developed for chronic heart failure and has shown efficacy in clinical trials.
  • Strong financial position with US$130 million cash balance at Dec 31, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.